Company intelligence / Profile preview

CureGen

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

CureGen is a South Korean biotechnology company specializing in molecular diagnostics and the development of novel gene therapies. Founded in 2000, the company leverages its proprietary DNA chip platform to create diagnostic tools for cancer and infectious diseases, including rapid testing kits for COVID-19. Beyond diagnostics, CureGen is actively engaged in research focused on gene therapy and DNA vaccines, aiming to address unmet medical needs in oncology and viral infections. The company's business model integrates the manufacturing of diagnostic reagents with long-term therapeutic R&D programs.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Gene therapyBiologicDNA vaccineSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on CureGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CureGen.

Explore the full profile